Acute GvHD: Pathogenesis and classification

Bone Marrow Transplantation

Volumn 41, Issue SUPPL. 2, 2008, Pages

  Ball, L M ^a   Egeler, R M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; CHILDHOOD DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DONOR LYMPHOCYTE INFUSION; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; RISK FACTOR; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

CHILD; GENETIC PREDISPOSITION TO DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTATION, HOMOLOGOUS;

EID: 45749156098     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.56     Document Type: Article

References (55)

1. Couriel A, Caldera H, Champlin R, Komanduri K. Acute graft versus host disease: Pathophysiology, clinical manifestations, and management. Cancer 2004; 101: 1936-1946.
2. Goker H, Haznedaroglu IC, Chao, NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
3. Billingham RE. The Biology of Graft-versus-host Disease. Academic Press Harvey Lecture: New York, 1966; 62: 21.
4. McCarthy NJ, Bishop MR. Non-myeloablative allogeneic stem cell transplantation: Early promise and limitations. Oncologist 2000; 5: 487-496.
5. Marks DI, Lush R, Caveriagh J. Milligan DW, Schey S. Parker A et al The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108-3114.
6. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003; 31: 865-872.
7. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism; and disease responses. Blood 2004; 103: 1548-1556.
8. Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse 1, Geserick G et al. Reduced intensity conditioning and prophylactic DL1 can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31: 339-345.
9. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: Possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696-1705.
10. Slavin S. Smarter rather than, stronger treatment of hematological malignancies and non-malignant indications for stem-cell transplantation. Lancet 2004: 364: 122-124.
11. Goker H. Haznedaroglu IC. Chao NJ. Acute graft-vs-host-disease: Pathobiology and management. Exp Hematol 2001; 29: 259-277.
12. Chao NJ. Graft-us-host disease. 2nd edn. RG Landes and Cd: Austin, USA, 1999.
13. Martin PJ, Gooley T. Anasetti C, Petersdorf EW. Hansen JA. HLAs and risk of acute graft-versus-host disease after marrow transplantation from and HLA identical sibling. Biol Blood Marrow Transplant 1998; 4: 128-133.
14. Bland PW, Whiting CV. Induction of MHC class II gene products in rat intestinal epithelium during graft-vs-host disease and effects of the immune system of the epithelium. Immunology 1992; 75: 366-371.
15. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism. Science 1992; 279: 1054-1057.
16. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor incompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
17. Dickinson AM, Charron D. Non HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Imunnol 2005; 17: 517-525.
18. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
19. Holler E, Rogler H, Herfarth H, Brenmoehl J, Wild PJ, Hahn J et al Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stein cell transplantation. Blood 2004; 104: 889-894.
20. Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H et al Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: Effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107 4189-4193.
21. Granell M, Urbano-Ispizua A, Aróstegui JI, Fernández-Avilés F. Martínez C. Rovira M et al. Effect of NOD2/CARD15 variants in T cell depleted allogeneic stem cell transplantation. Hematologica 2006; 91: 1372-4193.
22. Mullighan CG, Bardy PG. New directions in the genomic of allogeneic stein cell transplantation. Biol. Blood Marrow Transplant 2007; 13: 127-144.
23. Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR et al Prediction of graft versus host disease in humans by donor gene expression profiling. PLoS Med 2007; 4: E23.
24. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. Donor methylenetetra-hydrofolate reductase genotype is associated with graft versus host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 377: 773-779.
25. Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R et al. Methylenetetra-hydrofolate reductase and thymidylate synthase genotypes and risk of acute graft versus host disease following hematopoietic stem cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12: 973-980.
26. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
27. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187.
28. Zeiser R, Marks R, Bertz H, Finke J. Immune pathogenesis of acute graft-versus-host disease: Implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551-565.
29. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM et al Inflammatory cytokines and acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. Blood 2005; 106: 4407-4411.
30. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman R. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
31. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565-572.
32. Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001; 97: 2886-2895.
33. Wasem C, Frutschi C, Arnold D, Vallan C, Lin T, Green DR et al. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J Immunol 2001; 167: 2936-2941.
34. Rembereger M, Jaksch M, Uzunel M, Mattson J. Serum level of cytokines correlate to donor chimerism and acute graft-versus-host disease after hematopoietic stem cell transplantation. Blood 2003; 101: 2440-2445.
35. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
36. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Immunol 2002; 169: 7111-7118.
37. Jansssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8 + T lymphocytes. Nature 2003; 421: 852-856.
38. Ho VT, Kim HT, Li S, Hochberg EP, Cutler C, Lee SJ et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004; 34: 987-994.
39. Dieckman D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4 + CD25 + regulatory contact-dependent T cells induce interleukin 10-producing, contact independent type I like regulatory T cells. J Exp Med 2002; 196: 247-253.
40. Nakaruma K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4 + CD25 + regulatory T cells is mediated by cell surface transforming growth factor beta. J Exp Med 2001; 194 629-644.
41. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D et al. CD25 expression on donor CD4 + or CD8 + T cells is associated with an increased risk of graft versus host disease after HLA identical stem cell transplantation in humans. Blood 2004; 103: 1140-1146.
42. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M et al Chronic graft versus host disease is associated with increased numbers of peripheral blood CD4 + CD25 high regulatory T cells. Blood 2004; 103: 2410-2416.
43. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al Prevention of graft versus host disease by inactivation of host antigen presenting cells. Science 1999; 285: 412-415.
44. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393-7398.
45. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I. Jain D et al Donor APC's are required for maximal GvHD but not for GVL. Nat Med 2004; 10: 987-992.
46. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft versus host disease. J Immunol 1996; 157: 5387-5393.
47. Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A et al. Expression of chemokines in GvHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant 2006; 12: 623-634.
48. Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M et al. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 + T cells to skin in human graft verusus host disease. Br J Haematol 2006; 133: 538-549.
49. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
50. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N et al Risk factors.for acute graft versus host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1293.
51. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors. Blood 2001; 98: 2043-2051.
52. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft versus host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001; 19: 3695-3691.
53. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
54. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stem JM et al. An acute graft versus host disease activity index to predict survival after hematopoietic stem cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755.
55. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant 1995; 15: 825-828.